ANNIVERSARY OF STAN HYWET HALL & GARDENS

Mr. VOINOVICH (for himself and Mr. BROWN) submitted the following concurrent resolution, which was referred to the Committee on the Judiciary:

WHEREAS Stan Hywet Hall was built between 1912 and 1915 by Franklin ‘P.A.’ Augustus Seiberling and his wife, Gertrude; and

WHEREAS Franklin Seiberling hired architect Charles S. Schneider of Cleveland to design the house, landscape architect John H. Manning of Boston to design the grounds, and Hugo F. Huber of New York City to decorate the interior;

WHEREAS Stan Hywet Hall is one of the finest examples of Tudor Revival architecture in the United States;

WHEREAS Alcoholics Anonymous, an organization that continues to help millions of individuals worldwide recover from alcohol addiction, was founded on Mother’s Day 1935 following a meeting between Mr. Bill Wilson and Dr. James Bell hosted by Henrietta Seiberling at Stan Hywet Hall;

WHEREAS, in 1957, in keeping with the Stan Hywet Hall crest motto of ‘Non Nobis Solum (Not for us alone)’, the Seiberlings donated Stan Hywet Hall to a nonprofit organization, which came to be known as Stan Hywet Hall & Gardens, so that the public could enjoy the experience part of a noteworthy chapter in the history of the United States;

WHEREAS Stan Hywet Hall & Gardens is identified as a National Historic Landmark by the Department of the Interior, the only location in Akron, Ohio, with such a designation and one of only 2,200 nationwide;

WHEREAS Stan Hywet Hall & Gardens is one of Ohio’s top 10 tourist attractions, is a Save America’s Treasures project, and is accredited by the American Association of Museums;

WHEREAS more than 5,000,000 people from around the world have visited Stan Hywet Hall & Gardens, with the number of visitors annually averaging between 150,000 and 200,000 since 1999;

WHEREAS Stan Hywet Hall & Gardens contributes over $12,000,000 annually to the greater Akron economy;

WHEREAS Stan Hywet Hall & Gardens is a recipient of the Trustee Emeritus Award for Excellence in the Stewardship of Historic Sites, the National Trust for Historic Preservation, only the fourth recipient of the Award after George Washington’s Mount Vernon, Thomas Jefferson’s Monticello, and Washington, D.C.’s Octagon House; and

WHEREAS Stan Hywet Hall & Gardens relies on more than 1,300 volunteers to ensure that its doors remain open to the public, including an auxiliary volunteer board, the Friends of Stan Hywet, the Stan Hywet Glide, the Stan Hywet Needlework Guild, the Stan Hywet Flower Arrangers, the Stan Hywet Garden Committee, the Carriage House Gift Shop, the Conservatory, Vintage Base Ball, Vintage Explorers, the Akron Garden Club, and the Garden Forum of Greater Akron; now, therefore, be it

Resolved by the Senate (the House of Representatives concurring), That Congress—

(1) congratulates Stan Hywet Hall & Gardens on its 50th anniversary;

(2) honors Stan Hywet Hall & Gardens for its commitment to sharing its history, gardens, and art collections with the public; and

(3) directs the Secretary of the Senate to transmit a copy of this resolution to Stan Hywet Hall & Gardens.

AMENDMENTS SUBMITTED AND PROPOSED

SA 1034. Mr. DURBIN (for himself and Mr. BINGAMAN) submitted an amendment intended to be proposed by him to the bill S. 1082, to amend the Federal Food, Drug, and Cosmetic Act to mandate the prescription drug user fee provisions, and for other purposes; which was ordered to lie on the table.

SA 1035. Mr. BURR submitted an amendment intended to be proposed by him to the bill S. 1082, supra; which was ordered to lie on the table.

SA 1036. Mr. CORKER submitted an amendment intended to be proposed to amendment SA 990 submitted by Mr. DORGAN (for himself, Mr. SNOWE, Mr. GRASSLEY, Mr. MCCAIN, Mr. SPECTER, Mr. NELSON of Florida, Mr. PRYOR, Mr. SANDERS, Mr. WHITEHOUSE, and Mrs. MCCASKILL) to the bill S. 1082, supra; which was ordered to lie on the table.

SA 1037. Mr. VITTER submitted an amendment intended to be proposed by him to the bill S. 1082, supra; which was ordered to lie on the table.

SA 1038. Mr. GRASSLEY submitted an amendment intended to be proposed by him to the bill S. 1082, supra; which was ordered to lie on the table.

SA 1039. Mr. LAUTENBROOK (for herself and Mr. LAUTENHEER) submitted an amendment intended to be proposed by her to the bill S. 1082, supra; which was ordered to lie on the table.

SA 1040. Mrs. LINTON (for herself and Mr. LINTON) submitted an amendment intended to be proposed by him to the bill S. 1082, supra; which was ordered to lie on the table.

SA 1041. Mr. OBAMA submitted an amendment intended to be proposed by him to the bill S. 1082, supra; which was ordered to lie on the table.

SA 1042. Mr. ENSIGN submitted an amendment intended to be proposed by him to the bill S. 1082, supra; which was ordered to lie on the table.

SA 1043. Mr. WOOD (for himself and Mr. DODD) submitted an amendment intended to be proposed to amendment SA 1035 submitted by Mr. BURR and intended to be proposed to the bill S. 1082, supra; which was ordered to lie on the table.

SA 1044. Mr. KOHL submitted an amendment intended to be proposed by him to the bill S. 1082, supra; which was ordered to lie on the table.

TEXT OF AMENDMENTS

SA 1034. Mr. DURBIN (for himself and Mr. BINGAMAN) submitted an amendment intended to be proposed by him to the bill S. 1082, to amend the Federal Food, Drug, and Cosmetic Act to reauthorize and amend the prescription drug user fee provisions, and for other purposes; which was ordered to lie on the table; as follows:

In title II, strike subtitle D and insert the following:

Subtitle D—Conflicts of Interest

SEC. 241. CONFLICTS OF INTEREST.

(a) IN GENERAL.—Subchapter A of chapter VII of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 371 et seq.) is amended by inserting at the end the following:

“SEC. 721. CONFLICTS OF INTEREST.

“(a) DEFINITIONS.—For purposes of this section:

“(1) ADVISORY COMMITTEE.—The term ‘advisory committee’ means an advisory committee under the Federal Advisory Committee Act that provides advice or recommendations to the Secretary regarding activities of the Food and Drug Administration.

“(2) FINANCIAL INTEREST.—The term ‘financial interest’ means financial interest under section 208(a) of title 18, United States Code.

“(b) APPOINTMENTS TO ADVISORY COMMITTEES.—

“(1) RECRUITMENT.—

“(A) IN GENERAL.—Given the importance of advisory committees to decision making at the Food and Drug Administration, the Secretary, through the Office of Women’s Health, the Office of Orphan Product Development, the Office of Pediatric Therapeutics, and other offices within the Food and Drug Administration with relevant expertise, shall develop and implement strategies on effective outreach to propose members of advisory committees at universities, colleges, other academic research centers, professional and medical societies, and patient and consumer groups. The Secretary shall seek input from professional medical and scientific societies to determine the most effective informational and recruitment activities. The Secretary shall take into account the advisory committees with the greatest number of vacancies.

“(B) RECRUITMENT.—The recruitment activities under subparagraph (A) may include—

“(i) advertising the process for becoming an advisory committee member at medical and scientific society conferences;

“(ii) making widely available, including by using existing electronic communications channels, the contact information for the Food and Drug Administration point of contact regarding advisory committee nominations; and

“(iii) developing a method through which an entity receiving funding from the National Institutes of Health, the Agency for Healthcare Research and Quality, the Centers for Disease Control and Prevention, or the Veterans Health Administration can identify a person who the Food and Drug Administration can contact regarding the nomination of individuals to serve on advisory committees.

“(c) EVALUATION AND CRITERIA.—When considering a term appointment to an advisory committee, the Secretary shall consider the expertise of the individual and the financial disclosure report filed by the individual pursuant to the Ethics in Government Act of 1978 in determining whether the individual is qualified for the appointment, so as to reduce the likelihood that an appointed individual will later require a written determination as required for the purposes of the Food and Drug Administration, the Secretary, the Food and Drug Administration, the Agency for Healthcare Research and Quality, the Centers for Disease Control and Prevention, and the Veterans Health Administration.

“(d) PARTICIPATION OF GUEST EXPERT WITH FINANCIAL INTEREST.—Notwithstanding any other provision of this section, an individual with a financial interest with respect to any matter considered by an advisory committee may be allowed to participate in a meeting of an advisory committee as a guest expert if the Secretary determines that the individual’s financial interest will not have a material impact on the meeting. An individual participating as a guest expert may provide information and expert opinion, but shall not participate in any discussion or vote by the members of the advisory committee.

“(e) GRANTING AND DISCLOSURE OF WAIVERS.—

“(A) IN GENERAL.—Prior to a meeting of an advisory committee regarding a particular matter (as that term is used in section 208 of...
title 18, United States Code), each member of the committee who is a full-time Government employee or special Government employee shall disclose to the Secretary financial (a) and (b) in accordance with subsection (b) of section 208.

(2) **Financial Interest of Advisory Committee Member or Family Member.**—No member of an advisory committee may deal with any matter considered by the committee if such member or (an immediate family member of such member) has a financial interest that could be affected by the advice given to the Secretary with respect to such matter, excluding interests explained in regulations issued by the Director of the Office of Government Ethics as remote or inconsequential to affect the integrity of the services of the Government employee to which such regulations apply.

(3) **Waiver.**—The Secretary may grant a waiver of the prohibition in paragraph (2) if such waiver is necessary to afford the advisory committee essential expertise.

(4) **Limitations.**—(A) **One Waiver per Committee Meeting.**—Notwithstanding any other provision of this section, with respect to any advisory committee, the Secretary shall not grant more than 1 waiver under paragraph (3) per committee meeting.

(B) **Scientific Work.**—The Secretary may not grant a waiver under paragraph (3) for a member of an advisory committee when the member’s work is in the category of "scientific work." "Scientific work" includes the disclosure required under subsection (c)(5) other than information exempted from disclosure under section 552 of title 5, United States Code, and section 552a of title 5, United States Code.

(5) **Disclosure of Waiver.**—Notwithstanding section 107(a)(2) of the Ethics in Government Act (5 U.S.C. App.), the following shall apply:

(A) **15 OR MORE DAYS IN ADVANCE.**—As soon as practicable, but in no case later than 15 days prior to the beginning of an advisory committee meeting to which a written determination as referred to in section 208(b)(1) of title 18, United States Code, a written certification as referred to in section 208(b)(3) of title 18, United States Code, or a waiver as referred to in paragraph (3) applies, the Secretary shall disclose (other than information exempted from disclosure under section 552 of title 5, United States Code, and section 552a of title 5, United States Code (popularly known as the Freedom of Information Act) and the Privacy Act of 1974, respectively) on the Internet website of the Food and Drug Administration—

(i) the type, nature, and magnitude of the financial interest of the advisory committee member to which such determination, certification, or waiver applies; and

(ii) the reasons for the Secretary for such determination, certification, or waiver.

(B) **Less Than 30 Days In Advance.**—In the case of a financial interest that becomes known to the Secretary less than 30 days prior to the beginning of an advisory committee meeting to which a written determination as referred to in section 208(b)(1) of title 18, United States Code, a written certification as referred to in section 208(b)(3) of title 18, United States Code, or a waiver as referred to in paragraph (3) applies, the Secretary shall disclose (other than information exempted from disclosure under section 552 of title 5, United States Code, and section 552a of title 5, United States Code) on the Internet website of the Food and Drug Administration the description of the financial interest described in clauses (1) and (ii) of subparagraph (A) as soon as practicable after the Secretary makes such determination, certification, or waiver, but in no case later than the date of such meeting.

(d) **Public Record.**—The Secretary shall ensure that a copy of each record and description of each meeting of an advisory committee includes the disclosure required under subsection (c)(5) (other than information exempted from disclosure under section 552 of title 5, United States Code, and section 552a of title 5, United States Code).

(e) **February 1st.**—Notwithstanding any other provision of this section, the Secretary shall submitt to the Committee on Appropriations and the Committee on Commerce, Education, and Labor, and Pensions of the Senate, and the Committee on Appropriations and the Committee on Energy and Commerce of the House of Representatives a report that describes—

(1) with respect to the fiscal year that ended on September 30 of the previous year, the number of vacancies on each advisory committee and the percentage of individuals to whom such disclosures did not apply who served on such committee for each such meeting;

(2) with respect to such year, the aggregate number of waivers required under subsection (c)(5) for each meeting of each advisory committee and the percentage of individuals to whom such disclosures did not apply who served on such committee for each such meeting;

(3) with respect to such year, the number of times the disclosures required under subsection (c)(5) occurred under subparagraph (B) of such subsection; and

(4) how the Secretary plans to reduce the number of vacancies reported under paragraph (3) each year following such year, and mechanisms to encourage the nomination of individuals for service on an advisory committee, including those who are classified by the Food and Drug Administration as academicians or practitioners.

(f) **Periodic Review of Guidance.**—Not less than once every 5 years, the Secretary shall review the guidance of the Food and Drug Administration regarding conflict of interest waiver determinations with respect to advisory committees and update such guidance as necessary.

(g) **Conforming Amendment.**—Section 506(n) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 356(n)) is amended by—

(1) striking paragraph (4); and

(2) redesignating paragraphs (5), (6), (7), and (8) as paragraphs (4), (5), (6), and (7), respectively.

(h) **Effective Date.**—The amendments made by this section shall take effect on October 1, 2007.

**SA 1035.** Mr. BURR submitted an amendment intended to be proposed by him to the bill S. 1082, to amend the Federal Food, Drug, and Cosmetic Act to authorize and amend the prescription drug user fee provisions, and for other purposes; which was ordered to lie on the table; as follows:

At the end of the bill, insert the following:

**SEC. 2. ADDITION TO PRIORITY LIST CONSIDERATIONS.**

Section 409I of the Public Health Service Act (42 U.S.C. 289m), as amended by this Act, is further amended by—

(1) by striking subsection (a)(2) and inserting the following:

"(2) **ConsiDeration of Available Information.**—In developing and prioritizing the list under paragraph (1), the Secretary—

(A) shall consider—

(i) therapeutic gaps in pediatrics that may include developmental pharmacology, pharmacogenetic determinants of drug response, metabolism of drugs and biologics in children, and pediatric clinical trials; and

(ii) disorders, diseases, or conditions where more complete knowledge and testing of therapeutics, including drugs and biologics, may be beneficial in pediatrics;

(B) may consider the availability of qualified countermeasures (as defined in section 310 of the Public Health Service Act) and qualified countermeasure products (as defined in section 319F–3) to address the needs of pediatric populations, in consultation with the Assistant Secretary for Preparedness and Response; and

(C) shall review guidance of the Food and Drug Administration regarding conflict of interest waiver determinations with respect to advisory committees and update such guidance as necessary.

(2) by striking "(section (a) and inserting "(paragraphs (1) and (2) of subsection (a))."

**SA 1036.** Mr. CORKER submitted an amendment intended to be proposed to amendment SA 990 submitted by Mr. DURGAN (for himself, Mr. SNOWE, Mr. GAYLORD, Mr. MCCASKILL, Mr. NELSON of Florida, Mr. PRIYOR, Mr. SANDERS, Mr. WHITEHOUSE, and Mrs. MCCASKILL) to the bill S. 1082, to amend the Federal Food, Drug, and Cosmetic Act to reauthorize and amend the prescription drug user fee provisions, and for other purposes; which was ordered to lie on the table; as follows:

On page 88 of the amendment, strike lines 5 through 7 and insert the following:

"(a) the packaging, repackaging, labeling, relabeling, or distribution of a prescription drug;

(b) prohibition on commingling—

(1) in general.—A registered importer shall not commingle a prescription drug imported into the United States under this section with another prescription drug unless such other prescription drug is imported from a permitted country.

(2) label.—A registered importer (including, for the purposes of this subsection, an Internet pharmacy) that dispenses a prescription drug imported from a permitted country shall affix to each dispensed container of the prescription drug the label required under paragraph (3), unless such a label is already affixed to the container.

(3) requirements.—Each prescription drug imported under this section shall be in the original container, bearing, in prominent and conspicuous type—

(A) the lot number of the prescription drug;

(B) the name, address, and phone number of the exporter of the drug, regardless of whether the exporter is registered;

(C) the following statement: This drug has been imported from the permitted country with the name of the permitted country from which the prescription drug has imported in the blank space; and

(D) a unique identifier code provided by the Secretary that modifies the national drug code of the prescription drug to indicate that the drug has been imported;

(E) a statement that disclaims the originating country of the drug; and

(F) that the container complies with any other applicable requirement of this Act.

**SA 1037.** Mr. VITTER submitted an amendment intended to be proposed by him to the bill S. 1082, to amend the Federal Food, Drug, and Cosmetic Act to authorize and amend the prescription drug user fee provisions, and for other purposes; which was ordered to lie on the table; as follows:

At the appropriate place in the amendment, insert the following:

**SEC. 3. REQUIRED TESTING OF DRUGS.**

Notwithstanding any other provision of this title (and the amendment made by this title) a prescription drug may only be imported by a pharmacist, wholesaler, or individual under this title (or amendments) if
the importer of such drug complies with sub-
sections (d)(1) and (e) of section 804 of such
Act (21 U.S.C. 384(d)(1) and (e)), as in effect
on the day before the date of enactment of
this Act.

SA 1038. Mr. VITTER submitted an amend-
ment intended to be proposed by him
to the bill S. 1082, to amend the
Federal Food, Drug, and Cosmetic Act
to reauthorize and amend the prescrip-
tion drug user fee provisions, and for
other purposes; which was ordered to lie
on the table; as follows:

At the appropriate place in the amend-
ment, insert the following:

SEC. 2. REQUIRED FDA APPROVAL OF DRUGS.

Notwithstanding any other provision of
this title (and the amendment made by this
title) a prescription drug may only be im-
ported by a pharmacist, wholesaler, or indi-
vidual under this title (or amendments if—
(1) such drug complies with section 505 of
the Federal Food, Drug, and Cosmetic Act
(21 U.S.C. 355) including with respect to
being safe and effective for the intended use
(COSI effective for the intended use of the
prescription drug) and with sections 501 and
502 of such Act (21 U.S.C. 351 and 352);
(2) the importer of such drug complies with
subsections (d)(1) and (e) of section 804 of
such Act (21 U.S.C. 384(d)(1) and (e)), as in ef-
fact on the day before the date of enactment
of this Act;

(3) the drug or importer of such drug com-
plies with any additional requirements de-
termined by the Secretary of Health and Hu-
man Services to be appropriate as a safe-
guard to protect the public health or as a
means to facilitate the importation of pre-
scription drugs.

SA 1039. Mr. GRASSLEY submitted an amend-
ment intended to be proposed by him
to the bill S. 1082, to amend the
Federal Food, Drug, and Cosmetic Act
to reauthorize and amend the prescrip-
tion drug user fee provisions, and for
other purposes; which was ordered to lie
on the table; as follows:

At the end of subtitle E of title II, insert the
following:

SEC. 2. AUTHORITY OF THE OFFICE OF SUR-
VEILLANCE AND EPIDEMIOLOGY.

With respect to all actions of the Food and
Drug Administration related to post-
marketing drug safety, including labeling
changes, postapproval studies, and restric-
tions on distribution or use of drugs with ser-
ious risks, the Office of Surveillance and
Epidemiology (or successor office) of such
Administration and the Office of New Drugs
(or successor office) of such Administration
shall make decisions jointly. In the event of
a disagreement with respect to an action
related to postmarketing drug safety, in-
cluding labeling changes, postapproval stud-
ies, and restrictions on distribution or use of
drugs with serious risks, between such 2 of-
fices, the Commissioner of Food and Drugs
shall make the decision with respect to such
action.

SA 1040. Mrs. CLINTON (for herself
and Mr. LAUTENBERG) submitted an amend-
ment intended to be proposed by her
to the bill S. 1082, to amend the
Federal Food, Drug, and Cosmetic Act
to reauthorize and amend the prescrip-
tion drug user fee provisions, and for
other purposes; which was ordered to lie
on the table; as follows:

At the appropriate place, insert the fol-
lowing:

SEC. 3. LIABILITY OF HEALTHCARE PRO-
VIDERS.

A healthcare provider who prescribes, or
who dispenses without a prescription, a
drug, biologic product, or medical device
approved, licensed, or cleared by the Food
and Drug Administration shall not be deemed
as a party to any act involving the use of
such drug, biologic product, or medical de-
vice and shall not be liable to a claimant in
a class action lawsuit against the manufac-
turer, distributor, or seller of such drug, bi-
ological product, or medical device.

SA 1043. Mr. REED (for himself and
Mr. DOED) submitted an amendment in-
tended to be proposed to amendment
SA 1035 submitted by Mr. BURR and sub-
tended to be proposed to the bill S.
1082, to amend the Federal Food, Drug,
and Cosmetic Act to reauthorize and amend
the prescription drug user fee provisions,
and for other purposes; which was ordered to lie on the table; as follows:

In lieu of the matter proposed to be in-
serted, insert the following:

( ) ADDITION TO PRIORITY LIST CONSIDER-
ATIONS.—

(1) IN GENERAL.—Section 409L of the Public
Health Service Act (42 U.S.C. 300m), as
amended by this Act, is amended—

(A) by striking subsection (a)(2) and insert-
ning the following:

"(B) CHAIRPERSON.—The Secretary of Health
and Human Services shall serve as the chair-
person of the joint task force established
under subsection (a) shall—

(1) develop recommendations on how to ef-
tively address the problem of foodborne ill-
ness in the United States;

(2) submit to Congress recommendation for
changes in the law to address the sources of
food contamination before hazards enter the
food supply, such as mandatory recall au-
thority, trace back procedures, and modi-
fication to farm regulations; and

(3) identify measures to be taken at the
Federal agency level to effectively improve
internal and external communication and in-
formation sharing with respect to addressing
the problem of foodborne illness.

(d) PARTICIPATION AND INPUT OF OTHERS.—
The joint task force established under sub-
section (a) shall establish mechanisms to
allow inclusion of the following: farm-
ers, the food industry, consumer groups, and
relevant State agencies, to participate in
task force activities and to provide the task
force with input on food safety policy.

SA 1041. Mr. OBAMA submitted an amend-
ment intended to be proposed by him
to the bill S. 1082, to amend the
Federal Food, Drug, and Cosmetic Act
to reauthorize and amend the prescrip-
tion drug user fee provisions, and for
other purposes; which was ordered to lie
on the table; as follows:

At the appropriate place, insert the fol-
lowing:

SEC. 3. IMPROVING GENETIC TEST SAFETY
AND QUALITY.

Not later than 30 days after the date of en-
actment of this Act, the Secretary shall
enter into a contract with the Institute of
Medicine to conduct a study and prepare a
report that includes recommendations to im-
prove Federal oversight and regulation of ge-
netic tests. Such study shall take into con-
sideration relevant reports by the Sec-
retary’s Advisory Committee on Genetic
Testing and other groups and shall be com-
pleted not later than 1 year after the date on
which the Secretary entered into such con-
tract.

SA 1042. Mr. ENNSIGN submitted an amend-
ment intended to be proposed by him
to the bill S. 1082, to amend the
Federal Food, Drug, and Cosmetic Act
to reauthorize and amend the prescrip-
tion drug user fee provisions, and for
other purposes; which was ordered to lie
on the table; as follows:

At the appropriate place, insert the fol-
lowing:

SEC. 3. PROHIBITION ON IMPORTATION FROM
A FOREIGN FOOD FACILITY THAT
DENIES ACCESS TO FOOD INSPECTORS.

Notwithstanding any other provision of
law, no food product may be imported into
the United States that is the product of a
foreign facility registered under section 415
of the Federal Food, Drug, and Cosmetic Act
(21 U.S.C. 350d) that refuses to permit United
States inspectors to inspect such facility or that unduly delays access to
United States inspectors.
NOTICES OF HEARINGS
COMMITTEE ON ENERGY AND NATURAL RESOURCES
Mr. BINGAMAN. Mr. President, I would like to announce for the information of the Senate and the public that a hearing has been scheduled before the Committee on Energy and Natural Resources Subcommittee on National Parks.

The hearing will be held on May 15, 2007, at 2:30 p.m. in room SD–366 of the Dirksen Senate Office Building.

The purpose of the hearing is to receive testimony on the following bills:

S. 553, to amend the Wild and Scenic Rivers Act to designate certain segments of the Eightmile River in the State of Connecticut as components of the National Wild and Scenic Rivers System; S. 800, to establish the Niagara Falls National Heritage Area in the State of New York; S. 916, to modify the boundaries of the Minidoka National Historic Site, to authorize the Secretary of the Interior to convey certain land and improvements of the Gooding Division of the Minidoka Project, Idaho; S. 1057, to amend the National Wild and Scenic Rivers Act to designate certain segments of the New River in the States of North Carolina and Virginia as a component of the National Wild and Scenic Rivers System; S. 1291, to provide for the continued administration of Santa Rosa Island, Channel Islands National Park, in accordance with the laws (including regulations) and policies of the National Park Service; and S. 1293, to amend the Wild and Scenic Rivers Act to designate certain rivers and streams of the headwaters of the Snake River System as additions to the National Wild and Scenic River System; H.R. 161, to adjudge the property of the Manzanar Internment National Monument to include the Nidoto Nai Yoni Memorial in Bainbridge Island, Washington; H.R. 247, to designate a Forest Service trail at Waldo Lake in the Willamette National Forest in the State of Oregon as a national recreation trail in honor of Jim Weaver, a former Member of the House of Representatives; and H.R. 376, to authorize the Secretary of the Interior to conduct a special resource study to determine the feasibility of including the battlefields and related sites of the First and Second Battles of Newtonia, Missouri, during the Civil War as part of Wilson's Creek National Battlefield or designating the battlefields and related sites as a separate unit of the National Park System.

Because of the limited time available for the hearing, witnesses may testify by invitation only. However, those wishing to submit written testimony for the hearing record should send it to the Committee on Energy and Natural Resources, United States Senate, Washington, DC 20510–6190, or by e-mail to rachel_pasternack@energy.senate.gov.

For further information, please contact David Brooks at (202) 224–9863 or Rachel Pasternack at (202) 224–0883.

COMMITTEE ON INDIAN AFFAIRS
Mr. DORGAN. Mr. President, I would like to announce that the Committee on Indian Affairs will meet on Thursday, May 3, 2007, at 9:30 a.m. in room 405 of the Russell Senate Office Building to receive testimony on "A Summary of the Native Hawaiian Government Reorganization Act of 2007." Those wishing additional information may contact the Indian Affairs Committee at 224–2531.

AUTHORITY FOR COMMITTEES TO MEET
COMMITTEE ON ARMED SERVICES
Mr. DORGAN. Mr. President, I ask unanimous consent that the Committee on Armed Services be authorized to meet during the session of the Senate on Thursday, May 3, 2007, at 9:30 a.m., to receive testimony from Richard Joseph Sullivan to be U.S. District Judge for the Eastern District of New York; Joseph S. Van Bokkelen to be U.S. District Judge for the Northern District of Indiana; and Maureen Mauskopf to be U.S. District Judge for the Eastern District of New York; Richard Joseph Sullivan to be U.S. District Judge for the Southern District of New York; Joseph S. Van Bokkelen to be U.S. District Judge for the Northern District of Indiana.

OFFICE OF THE PRESIDENT
The PRESIDING OFFICER. Without objection, it is so ordered.

COMMITTEE ON COMMERCE, SCIENCE, AND TRANSPORTATION
Mr. DORGAN. Mr. President, I ask unanimous consent that the Committee on Commerce, Science, and Transportation be authorized to hold a hearing during the session of the Senate on Thursday, May 3, 2007, at 3 p.m., in room 253 of the Russell Senate Office Building. The purpose of the hearing is to receive testimony on "2007 Corporate Average Fuel Economy Legislation and related matters." The PRESIDING OFFICER. Without objection, it is so ordered.

COMMITTEE ON COMMERCE, SCIENCE, AND TRANSPORTATION
Mr. DORGAN. Mr. President, I ask unanimous consent that the Committee on Commerce, Science, and Transportation be authorized to hold a hearing during the session of the Senate on Thursday, May 3, 2007, at 10 a.m., in 215 Dirksen Senate Office Building, to receive testimony on "Offshore Tax Evasion: Stashing Cash Overseas." The PRESIDING OFFICER. Without objection, it is so ordered.

COMMITTEE ON HOMELAND SECURITY AND GOVERNMENTAL AFFAIRS
Mr. DORGAN. Mr. President, I ask unanimous consent that the Committee on Homeland Security and Governmental Affairs be authorized to meet on Thursday, May 3, 2007, at 10 a.m., for a hearing titled "The Internet: A Portal to Violent Islamist Extremism."

The PRESIDING OFFICER. Without objection, it is so ordered.

COMMITTEE ON THE JUDICIARY
Mr. DORGAN. Mr. President, I ask unanimous consent that the Committee on the Judiciary be authorized to meet to conduct a markup on Thursday, May 3, 2007, at 10 a.m. in Dirksen Room 226.

Agenda
III. Nominations: Debra Ann Livingston to be U.S. Circuit Judge for the Second Circuit; Roslynn Renee Mauskopf to be U.S. District Judge for the E. District of New York; Richard Joseph Sullivan to be U.S. Dis- trict Judge for the Southern District of New York; Joseph S. Van Bokkelen to be U.S. District Judge for the Northern District of Indiana.

OFFICE OF THE PRESIDENT
The PRESIDING OFFICER. Without objection, it is so ordered.

SEAPOWER SUBCOMMITTEE
Mr. DORGAN. Mr. President, I ask unanimous consent that the Seapower Subcommittee of the Committee on Armed Services be authorized to meet during the session of the Senate on Thursday, May 3, 2007, at 2:30 p.m., in closed and open sessions to receive testimony on Navy Force structure require- ments and programs to meet then requirements in review of the defense authorization request for fiscal year 2008 and the future years defense program.

The PRESIDING OFFICER. Without objection, it is so ordered.

SELECT COMMITTEE ON INTELLIGENCE
Mr. DORGAN. Mr. President, I ask unanimous consent that the Select Committee on Intelligence be authorized to meet during the session of the Senate on May 3, 2007, at 2:30 p.m. to hold a business meeting.

The PRESIDING OFFICER. Without objection, it is so ordered.

SUBCOMMITTEE ON PUBLIC LANDS AND FORESTS
Mr. DORGAN. Mr. President, I ask unanimous consent that the Subcommittee on Public Lands and Forests of the Committee on Energy and Natural Resources be authorized to hold a hearing during the session of the Senate on Thursday, May 3, 2007 at 2:30 p.m. in room 405 of the Dirksen Senate Office Building.

The purpose of the hearing is to receive testimony on the following bills:

S. 205 and H.R. 865, to grant rights-of- way for electric transmission lines over certain Native allotments in the State of Alaska; S. 390, to direct the ex- change of certain land in Grand, San Juan, and Uintah Counties, Utah; S. 647, to designate certain land in the State of Oregon as wilderness; S. 1199, to establish the Escalante-Grand Staircase Conservation System; H.R. 276, to design- ate the Piedras Blancas Light Sta- tion and the surrounding public land as